ECCO News

ECCO News keeps ECCO Members up-to-date on what is going on within the organisation and reports on IBD activities taking place within Europe. Since Spring 2006, ECCO News has maintained the flow of information between Members of the organisation. 

ECCO News is an important part of the European Crohn’s and Colitis Organisation’s ambition to create a European standard of IBD care and to promote knowledge and research in the field of IBD. ECCO Members automatically receive this publication four times a year. 

Editor & Associate Editors

Alessandro Armuzzi
© Alessandro Armuzzi

Nuha Yassin
© ECCO

Ignacio Catalán-Serra
© Ignacio Catalán-Serra

Brigida Barberio
© Brigida Barberio

Spyros Siakavellas
© Spyros Siakavellas

Latest ECCO News Content


13October2022

Meet the JCC Authors: Podcast with Floris de Voogd

Ignacio Catalán-Serra, ECCO News Associate Editor

I. Catalán-Serra
© I. Catalán-Serra

Dear ECCO friends and family,

We are delighted to announce the new series of podcast of the Journal of Crohns and Colitis (JCC)! The editorial team of ECCO News is taking over the task to bring you the best articles of JCC in a short and entertaining interview format. The authors will comment on their findings and we will discuss future directions and new areas of research in the topic and in the field of IBD.

In this first episode, we will dive into new applications of intestinal ultrasound in IBD and its potential as non-invasive method with Dr. de Voogd from Amstrerdam UMC from the article entitled: «Intestinal Ultrasound Early on in Treatment Follow-up Predicts Endoscopic Response to Anti-TNFα Treatment in Crohn’s Disease».

Welcome to our new podcast: Meet the JCC Authors !

Posted in ECCO News, Meet the JCC Authors, Volume 17, Issue 3

13October2022

Meet the Reps: France - Interview with Maeva Charkaoui & Anthony Buisson

Nuha Yassin, ECCO News Associate Editor

Nuha Yassin
© Nuha Yassin

Dear ECCO friends and family,

It is my pleasure to introduce the National Representatives of France at ECCO, Maeva Charkaoui & Anthony Buisson. We hope you enjoy getting to know them through this interview.

Best Wishes,

Nuha Yassin

Consultant Colorectal Surgeon

ECCO News Associate Editor

Posted in ECCO News, Meet the Reps, Volume 17, Issue 3

13October2022

Y-ECCO Interview Corner: Nicole Eichinger

Robin Dart, Y-ECCO Member

Robin Dart
© ECCO

ECCO is an ever-expanding organisation with educational activities which extend throughout the year. For this ECCO News I spoke with Nicole Eichinger, the Executive Director of ECCO, to find out a bit more about her and how the ECCO Team work behind the scenes to keep this vital organisation running as smoothly as it does.

Posted in ECCO News, Committee News, Volume 17, Issue 3, Y-ECCO

13October2022

Y-ECCO Literature Review: Chirag Patel

Chirag Patel

Inflammatory bowel disease patient-reported quality assessment should drive service improvement: a national survey of UK IBD units and patients

Hawthorne AB, Glatter J, Blackwell J, et al.

Aliment Pharmacol Ther. 2022;56:625–45.


Chirag Patel
© Chirag Patel

Introduction

In the United Kingdom (UK), approximately 500,000 people live with IBD, and in the coming decade it is anticipated that the prevalence of IBD will surpass 1% of the population [1]. In 2019, the third UK IBD Standards for adults and children were published following extensive patient and healthcare professional consultation [2]. The IBD Standards cover seven domains: service design and delivery; pre-diagnosis referral pathways; management of the newly diagnosed patient; flare management, including self-management and timely access to specialist advice; surgery including pre- and postoperative care; inpatient medical care; and ongoing long-term treatment and monitoring in both secondary and primary care.

Posted in ECCO News, Y-ECCO Literature Reviews, Committee News, Volume 17, Issue 3, Y-ECCO

13October2022

Y-ECCO Literature Review: Esha Sharma

Esha Sharma

Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population-based study

Jayasooriya N, Blackwell J, Saxena S, et al.

Aliment Pharmacol Ther 2022;55:1330–41.


Esha Sharma
© Esha Sharma

Introduction

Inflammatory Bowel Disease (IBD) is a long-term condition of the gut which is known to impact the quality of life and social functioning of those affected due to the chronic nature of symptoms. These factors, along with communication across the gut–brain axis, cause many patients to suffer from mental health disorders such as anxiety and depression [1]. Previously, the magnitude of these comorbidities had not been established, but recent studies [1, 2] have found the prevalence to be high: a third of all patients and a half of those with an active IBD flare have been found to suffer from anxiety, while depression has been found to affect a quarter of patients and a third of those with active symptoms.

Furthermore, compared with controls, patients with IBD and mental health disorders show increased use of healthcare resources (both primary care visits and emergency secondary care visits) and increased use of antidepressant and anxiolytic medications [2]. While antidepressant medications are commonly used to treat anxiety and depression in IBD [3], understanding of how effectively these treatments are prescribed remains limited, and this is particularly true regarding the adequacy of duration of treatment in this cohort.

This population-based study was performed in the United Kingdom and used data from the primary care setting that was routinely collected electronically in general practices as part of the Clinical Practice Research Datalink (CPRD). The authors looked to review the antidepressant prescribing in primary care for those diagnosed with IBD. They focused on the rate of antidepressant treatment initiation following IBD diagnosis, the duration of antidepressant treatment according to international guidelines, potential risks of inadequate antidepressant treatment duration and general trends in antidepressant prescribing.

Posted in ECCO News, Y-ECCO Literature Reviews, Committee News, Volume 17, Issue 3, Y-ECCO

13October2022

Y-ECCO Literature Review: Benjamin Zare

Benjamin Zare

Patient satisfaction of propofol versus midazolam and fentanyl sedation during colonoscopy in inflammatory bowel disease

Steenholdt C, Jensen JT, Brynskov J, et al.

Clin Gastroenterol Hepatol. 2022;20:559–68.e5


Benjamin Zare
© Benjamin Zare

Introduction

Many clinicians have anecdotally observed patients opting out of colonoscopies due to unpleasantness related to the procedure, and within Inflammatory Bowel Disease (IBD) populations a number of factors have been implicated in non-adherence, including logistics, health perceptions, stress and procedure problems (including discomfort) [1].

Prior studies have demonstrated patient preferences for propofol sedation over midazolam and fentanyl sedation for outpatient colonoscopy in general [2]. Furthermore, propofol has been shown to be safe, without severe adverse events or accidents [3], and nurse-administered propofol has specifically proven to be an efficient means of sedation for endoscopy in low-risk patients [4]. Nevertheless, this area has yet to be explored in the specific cohort of IBD patients.

Modern management of IBD requires the employment of ileocolonoscopy for diagnosis, as well as for the surveillance and guidance of future management. The investigators here looked to fill the aforementioned knowledge gap through design of a trial investigating the effectiveness of deep nurse-administered propofol sedation (NAPS), versus moderate midazolam and fentanyl sedation, as a means of improving patient satisfaction and future attitude towards colonoscopies.

Posted in ECCO News, Y-ECCO Literature Reviews, Committee News, Volume 17, Issue 3, Y-ECCO

13October2022

Finally, the first Y-ECCO Mentorship Forum!

Bram Verstockt, Y-ECCO Member

Bram Verstockt
© ECCO

Dear Y-ECCO Friends,

For very well-known pandemic reasons, we twice had to postpone the first Y-ECCO Mentorship Forum. Our third appointment with ECCO History proved to be the right one: in June 2022 we finally succeeded in completing our first Y-ECCO Mentorship Forum. Thanks to very active Y-ECCO participants and a stellar ECCO Faculty (Ailsa Hart, Peter Irving, Charlie Lees, Janneke Van der Woude and Johan Burisch), this networking and educational event was a great success. .

Posted in ECCO News, Committee News, Volume 17, Issue 3, Y-ECCO

13October2022

Y-ECCO Members’ Address

Charlotte Hedin, Y-ECCO Chair

Charlotte Hedin
© ECCO

Dear Y-ECCO Friends,

I hope you have all had time to re-charge over the summer! ECCO'23 abstract submission is currently open, with a deadline of November 21. Basic science abstracts can be considered for an Oral Presentation during the 9th Y-ECCO Basic Science Workshop, which will be held on Wednesday, March 1, 2023, between 13:05 and 15:30 CET – please tick the box if you are a Y-ECCO Member and would like to be part of this great interactive session.

Posted in ECCO News, Committee News, Volume 17, Issue 3, Y-ECCO

13October2022

New Developments to Standardise the Assessment of Mucosal Histology in Crohn’s Disease

Gert de Hertogh, H-ECCO Chair

Gert de Hertogh
© ECCO

The past 6 months of 2022 have seen the publication of two important papers, one by F. Magro et al. (“The ECCO position on harmonisation of Crohn’s disease mucosal histopathology” [1]) and the other by I.O. Gordon et al. (“International consensus to standardise histopathological scoring for small bowel strictures in Crohn’s disease” [2]).

Posted in ECCO News, Committee News, Volume 17, Issue 3, H-ECCO

13October2022

Personalised therapies in IBD: utilising next-generation sequencing data to direct treatment in monogenic disorders

Dror Shouval, P-ECCO Member

Dror Shouval
© ECCO

Over the past two decades, significant progress has been made in the understanding of the role of genetics in the pathogenesis of Inflammatory Bowel Disease (IBD): On the one hand, adult IBD studies have identified more than 250 single nucleotide polymorphisms that increase the risk of disease, though their individual and overall effect on the risk of developing IBD is small [1]. On the other hand, the expanding use of next-generation sequencing (NGS) platforms has resulted in the identification of more than 100 different rare monogenic disorders that directly cause IBD [2]. Given the central role of immune cells in sustaining immune tolerance in the gut, it is not surprising that in many cases monogenic disorders causing IBD result from pathogenic variants in genes involved in essential immune or epithelial pathways. Some patients with such disorders present with a clear immunodeficiency phenotype (e.g. chronic granulomatous disease, Wiskott-Aldrich syndrome), but in others IBD is the sole manifestation [3].

Posted in ECCO News, Committee News, Volume 17, Issue 3, P-ECCO